Ishares Biotechnology Etf Price To Book
| IBB Etf | USD 128.37 1.88 1.49% |
iShares Biotechnology ETF fundamentals help investors to digest information that contributes to IShares Biotechnology's financial success or failures. It also enables traders to predict the movement of IShares Etf. The fundamental analysis module provides a way to measure IShares Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IShares Biotechnology etf.
IShares |
iShares Biotechnology ETF ETF Price To Book Analysis
IShares Biotechnology's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current IShares Biotechnology Price To Book | 3.39 X |
Most of IShares Biotechnology's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, iShares Biotechnology ETF is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
IShares Biotechnology Price To Book Component Assessment
Based on the latest financial disclosure, iShares Biotechnology ETF has a Price To Book of 3.39 times. This is much higher than that of the iShares family and 12.07% higher than that of the Health category. The price to book for all United States etfs is notably lower than that of the firm.
Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Fund Asset Allocation for IShares Biotechnology
The fund invests 99.93% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides IShares Biotechnology's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
IShares Fundamentals
| Price To Earning | 3.16 X | |||
| Price To Book | 3.39 X | |||
| Price To Sales | 4.94 X | |||
| Earnings Per Share | (11.38) X | |||
| Beta | 0.8 | |||
| Market Capitalization | 9.22 B | |||
| Total Asset | 7.41 B | |||
| One Year Return | (1.40) % | |||
| Three Year Return | (6.90) % | |||
| Five Year Return | 3.60 % | |||
| Ten Year Return | 5.60 % | |||
| Net Asset | 7.41 B | |||
| Last Dividend Paid | 0.39 | |||
| Equity Positions Weight | 99.93 % |
About IShares Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze iShares Biotechnology ETF's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IShares Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of iShares Biotechnology ETF based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out IShares Biotechnology Piotroski F Score and IShares Biotechnology Altman Z Score analysis. Note that the iShares Biotechnology ETF information on this page should be used as a complementary analysis to other IShares Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.